目的 本文探讨口服不同剂量的蒙药亚森希莫-I，对去势所致大鼠骨质疏松的作用机制。方法 将3月龄SD大鼠60只、均为雌性，体重约220±20 g左右，随机分为空白组、模型组（均用等量生理盐水），阳性对照组（骨肽片400mg.kg-1）、低剂量亚森希莫-I（200mg.kg-1），中剂量亚森希莫-I（400mg.kg-1），高剂量亚森希莫-I（800mg.kg-1）组，每组10只。制作模型成功后，各组连续灌胃12周后，进行骨密度、骨生物力学、组织病理形态、Wnt1、BMP2等指标检测。结果 与空白组相比，模型组大鼠骨密度降低，骨质变细、断裂，BMP2蛋白和WNT1含量明显降低，差异具有统计学意义（P＜0.05）；与模型组相比，蒙药组和阳性对照组大鼠骨密度和骨量具有增高，骨生物力学载荷与刚度增加，骨组织形态密集，Wnt1、BMP2基因表达明显，差异均有统计学意义（P＜0.01）。与阳性对照组比较，治疗组大鼠各项指标无明显变化，结果无统计学意义（P＞0.05）。结论 蒙药亚森希莫-I改善骨质疏松症，可能与Wnt1/BMP2信号通路有关。

Objective To investigate the effect of different doses of Mongolian medicine Yasenximo-I on castration-induced osteoporosis in rats. Methods Sixty 3-month-old SD rats, all female and weighing about 220±20 g, were randomly divided into blank group, model group (all treated with the same amount of normal saline), positive control group (400mg.kg-1 osteopeptin tablets) and low-dose Yassenximo-I (200mg.kg-1). Medium dose Yasenximo-I (400mg.kg-1) and high dose Yasenximo-I (800mg.kg-1) groups were divided into 10 animals in each group. After successful modeling, bone mineral density, bone biomechanics, histopathologic morphology, Wnt1, BMP2 and other indicators were detected in each group after continuous gavage for 12 weeks. Results Comparedwith blank group, bone mineral density, bone thinning and fracture, BMP2 protein and WNT1 contents were significantly decreased in model group, and the difference was statistically significant (P < 0.05). Compared with model group, bone mineral density and bone mass of rats in Mongolian medicine group and positive control group were increased, bone biomechanical load and stiffness were increased, bone tissue morphology was dense, Wnt1 and BMP2 gene expressions were obvious, the differences were statistically significant (P < 0.01). Compared with the positive control group, there was no significant change in each index in the treatment group (P > 0.05). Conclusion Mongolian medicine Yasenximo-I can improve osteoporosis, which may be related to Wnt1/BMP2 signaling pathway.

2022年度江苏省研究生科研创新计划项目（编号KYCX22_1922）；内蒙古自治区自然科学基金面上项目（2020MS08134）